

Retifanlimab: Adis Evaluation

Key Points

- A programmed cell death 1 receptor-blocking antibody is being developed by Incyte Corporation for the treatment of solid tumours
- Received its first approval on 22 Mar 2023 in the USA
- Approved for use in adults with metastatic or recurrent locally advanced Merkel cell carcinoma under accelerated approval

Summary

Retifanlimab (retifanlimab-dlwr; ZYNYZ™) is a programmed cell death 1 receptor–blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents.

Retifanlimab recently received accelerated approval for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

This article summarizes the milestones in the development of retifanlimab leading to this first approval for Merkel cell carcinoma.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2023.